All News
Filter News
Found 796,712 articles
-
Tome Biosciences has only been on the scene for a short time but on Tuesday notched an acquisition of CRISPR-based biotech Replace Therapeutics for $65 million upfront.
-
Asensus Surgical, Inc. to Present at the 42nd Annual J.P. Morgan Healthcare Conference
1/3/2024
Asensus Surgical, Inc. announced that the management team will participate and present at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024 at 3:00pm EST.
-
Karyopharm to Present at 42nd Annual J.P. Morgan Healthcare Conference
1/3/2024
Karyopharm Therapeutics Inc. announced that the Company's senior management team will participate at the 42nd Annual J.P. Morgan Healthcare Conference in a podium presentation on Wednesday, January 10 at 2:15 p.m. PT, followed by a question-and-answer breakout session at 2:35 p.m. PT.
-
Editas Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference
1/3/2024
Editas Medicine, Inc., a clinical-stage genome editing company, announced that the Company’s President and CEO Gilmore O’Neill, M.B., M.M.Sc., will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, 4:30 p.m. PT / 7:30 p.m. ET in San Francisco, CA.
-
SELLAS Provides Corporate Updates and Highlights Key Upcoming Milestones
1/3/2024
SELLAS Life Sciences Group, Inc. provided a business update and will host a corporate webinar at 8:30 am ET.
-
Leap Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference
1/3/2024
Leap Therapeutics, Inc. announced that Douglas E. Onsi, President and Chief Executive Officer, will present a corporate overview at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
-
Entrada Therapeutics Promotes Nathan J. Dowden to President
1/3/2024
Entrada Therapeutics, Inc. announced that Nathan J. Dowden, current Chief Operating Officer of Entrada Therapeutics, has been promoted to President and Chief Operating Officer, effective as of January 1, 2024.
-
Verrica Pharmaceuticals Announces Specialty Pharmacy Partnership Agreement with Walgreens to Distribute YCANTH™
1/3/2024
Verrica Pharmaceuticals Inc., a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, announced that it is growing its distribution network by entering into an agreement with Walgreen Co. to distribute YCANTH™ through its specialty pharmacy.
-
Brii Biosciences Appoints Dr. Brian Alvin Johns as Chief Scientific Officer
1/3/2024
Brii Biosciences Limited, a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet need, is pleased to announce the appointment of Dr. Brian Alvin Johns, Ph.D., as Chief Scientific Officer, effective January 3, 2024.
-
Amicus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
1/3/2024
Amicus Therapeutics announced that Bradley Campbell, President and Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 8, 2024, at 2:15 p.m. PT.
-
Elektrofi and Janssen Biotech Enter Worldwide Collaboration and License Agreement to Exclusively Develop up to Five Programs Utilizing Elektrofi’s Formulation Technology
1/3/2024
Elektrofi, Inc. announced that it has entered a multi-target worldwide research collaboration and license agreement with Janssen Biotech, Inc., a Johnson & Johnson company.
-
Bruker Acquires Electron Microscopy Company Nion
1/3/2024
Bruker announced that it has acquired Nion, a privately-held company that develops and manufactures innovative high-end scanning transmission electron microscopes.
-
Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
1/3/2024
Atea Pharmaceuticals, Inc. announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea, will present a business update at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 10:30 a.m. PT in San Francisco, CA.
-
BioCryst to Present at 42nd Annual J.P. Morgan Healthcare Conference
1/3/2024
BioCryst Pharmaceuticals, Inc. announced that the company will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 9, 2024, at 6:00 p.m. ET.
-
ABVC BioPharma and its Subsidiary Receive $460M From AiBtl BioPharma as the First Milestone Payment of Global Licensing Fees
1/3/2024
ABVC BioPharma, Inc. and its subsidiary BioLite, Inc. announced that the Company and its subsidiary received an aggregate of 46 million shares from AiBtl BioPharma Inc., as its first milestone payment under a global licensing agreement.
-
BioCentriq® Announces the Successful Completion of $29.2M Series A Further Strengthening Cell Therapy Contract Development and Manufacturing Services
1/3/2024
BioCentriq®, a global cell-based therapy Contract Development and Manufacturing Organization, proudly announces the successful completion of its latest round of fundraising, securing $29.2M in capital investment.
-
XORTX Submits a New Patent for the Treatment of Chronic Kidney Disease
1/3/2024
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces submission of a new patent for the treatment of chronic kidney disease.
-
Melt Pharmaceuticals Provides Corporate Update - Jan 03, 2024
1/3/2024
Melt Pharmaceuticals, Inc., a clinical‑stage pharmaceutical company developing novel approaches for procedural sedation, provided a corporate update.
-
Dyne Therapeutics Announces Positive Initial Clinical Data from ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients Demonstrating Promise of the FORCE™ Platform in Developing Therapeutics for Rare Muscle Diseases
1/3/2024
Dyne Therapeutics, Inc. announced positive initial clinical data from its ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 and its DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy who are amenable to exon 51 skipping.
-
Frontier Medicines to Present at the 42nd Annual J.P. Morgan Healthcare Conference
1/3/2024
Frontier Medicines Corporation announced that Chris Varma, Ph.D., Frontier’s co-founder, chairman, and CEO, will present a company overview at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 at 11:30 a.m. PT.